A study published this week shows that taking retinol, a form of vitamin A, results in a decrease in the risk of developing melanoma. The effect is limited to those who took vitamin A in excess of standard multivitamin guidelines and was more pronounced in women than in men.
Cancer Network Editors
In a rare case where the side effect of a cancer treatment can be explained through molecular studies, researchers have identified the reason behind the frequent skin lesion side effect among metastatic melanoma patients that take the newly approved drug vemurafenib.
CancerNetwork highlights four sessions--on anaplastic large cell lymphoma, lymphoma in pregnancy, follicular lymphoma, splenic marginal zone lymphoma--you won’t want to miss from this year’s ASH.
Immunotherapy is finally getting the cancer clinical and research community excited: A large portion of the presentation and discussion at the Melanoma International Congress, held in Tampa, Florida last week focused on immunotherapy approaches for the treatment of the disease.
The theme of the SMR meeting in Tampa this year was “Advancement through Collaboration," and this theme was clearly reflected in the meeting.
With positive read-outs from trials over the last two years and approval of two new agents for the disease, Yervoy and Zelboraf, the field is already looking to new agents and combination trials to improve patient outcomes and survival.
Researchers at UCLA have engineered “vaults,” barrel-shaped nanoscale capsules found in the cytoplasm of mammalian cells, to slowly release chemokine CCL21 into tumors. CCL21 is a protein that, in pre-clinical studies in mice with lung cancer, stimulated the immune system to recognize and attack the cancer cells.
AstraZeneca today announced that the orphan drug vandetanib is now available to U.S. patients for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.
The study represents one of the largest cancer genomics investigations reported, with more than 10 trillion chemical bases of DNA sequenced. While its results underscore the complexity of breast cancer biology, the mutations uncovered may provide further clues to inform personalized therapy of this common breast cancer subtype.
Speaking at the ACCC last Friday, Sean Tunis, founder and director of the Center for Medical Technology Policy, gave a basic primer on what he sees as the primary goal of comparative effectiveness research.